Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn’s disease in Europe: a retrospective observational study

BACKGROUND: Vedolizumab (VDZ), a gut-selective anti-lymphocyte trafficking integrin antibody, is effective in treating patients with moderately to severely active Crohn’s disease (CD). In this study, we examined the real-world effectiveness and safety of induction therapy using VDZ alone or in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Weisshof, Roni, Vavricka, Stephan R., Pouillon, Lieven, Braegger, Fiona, Roset, Montserrat, Bent-Ennakhil, Nawal, Ferrante, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688148/
https://www.ncbi.nlm.nih.gov/pubmed/38030966
http://dx.doi.org/10.1186/s12876-023-03032-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688148/
https://www.ncbi.nlm.nih.gov/pubmed/38030966
http://dx.doi.org/10.1186/s12876-023-03032-7

Ejemplares similares